Concepts (168)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Intensive Care Units, Pediatric | 15 | 2018 | 70 | 2.730 |
Why?
|
| Erythrocyte Transfusion | 16 | 2022 | 77 | 2.550 |
Why?
|
| Anemia | 14 | 2022 | 132 | 1.680 |
Why?
|
| High-Frequency Ventilation | 4 | 2016 | 5 | 1.620 |
Why?
|
| Critical Illness | 18 | 2022 | 330 | 1.590 |
Why?
|
| Respiratory Insufficiency | 4 | 2018 | 154 | 1.080 |
Why?
|
| Child | 29 | 2023 | 4607 | 1.010 |
Why?
|
| Extracorporeal Membrane Oxygenation | 2 | 2021 | 66 | 0.760 |
Why?
|
| Hospitalization | 3 | 2017 | 1392 | 0.750 |
Why?
|
| Hospice Care | 1 | 2023 | 75 | 0.750 |
Why?
|
| Evidence-Based Medicine | 13 | 2022 | 460 | 0.680 |
Why?
|
| Palliative Care | 1 | 2023 | 249 | 0.670 |
Why?
|
| Respiration, Artificial | 4 | 2016 | 298 | 0.630 |
Why?
|
| Isoflurane | 2 | 2012 | 16 | 0.620 |
Why?
|
| Anesthetics, Inhalation | 2 | 2012 | 18 | 0.610 |
Why?
|
| Critical Care | 15 | 2022 | 402 | 0.560 |
Why?
|
| Hemoglobins | 3 | 2018 | 136 | 0.550 |
Why?
|
| Child, Preschool | 13 | 2018 | 2061 | 0.540 |
Why?
|
| Hemorrhage | 4 | 2022 | 286 | 0.510 |
Why?
|
| Infant | 11 | 2022 | 1693 | 0.480 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 1 | 2016 | 13 | 0.470 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 142 | 0.460 |
Why?
|
| Hypoxia | 1 | 2016 | 120 | 0.440 |
Why?
|
| Antidotes | 1 | 2014 | 15 | 0.420 |
Why?
|
| Poisoning | 1 | 2014 | 27 | 0.410 |
Why?
|
| Attitude to Death | 1 | 2012 | 19 | 0.370 |
Why?
|
| Group Processes | 1 | 2012 | 41 | 0.370 |
Why?
|
| Bronchial Spasm | 1 | 2012 | 8 | 0.360 |
Why?
|
| Medical Staff, Hospital | 1 | 2012 | 59 | 0.360 |
Why?
|
| Phlebotomy | 1 | 2012 | 6 | 0.360 |
Why?
|
| Humans | 35 | 2023 | 65140 | 0.360 |
Why?
|
| Naloxone | 1 | 2011 | 53 | 0.330 |
Why?
|
| Narcotic Antagonists | 1 | 2011 | 133 | 0.300 |
Why?
|
| Environmental Exposure | 1 | 2011 | 226 | 0.290 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2014 | 706 | 0.290 |
Why?
|
| Practice Guidelines as Topic | 3 | 2018 | 734 | 0.270 |
Why?
|
| Buprenorphine | 1 | 2011 | 198 | 0.270 |
Why?
|
| Infant, Newborn | 7 | 2018 | 1422 | 0.260 |
Why?
|
| Athetosis | 1 | 2007 | 2 | 0.250 |
Why?
|
| Atracurium | 1 | 2007 | 2 | 0.250 |
Why?
|
| Status Asthmaticus | 1 | 2007 | 6 | 0.250 |
Why?
|
| Chorea | 1 | 2007 | 10 | 0.250 |
Why?
|
| Neuromuscular Blocking Agents | 1 | 2007 | 15 | 0.250 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2007 | 126 | 0.220 |
Why?
|
| Adolescent | 7 | 2018 | 6297 | 0.220 |
Why?
|
| Internship and Residency | 1 | 2012 | 800 | 0.220 |
Why?
|
| Age Distribution | 2 | 2014 | 262 | 0.180 |
Why?
|
| Community Health Services | 1 | 2023 | 127 | 0.180 |
Why?
|
| New England | 2 | 2014 | 271 | 0.180 |
Why?
|
| Transfusion Reaction | 2 | 2018 | 45 | 0.170 |
Why?
|
| Liquid Ventilation | 1 | 2001 | 4 | 0.170 |
Why?
|
| Tay-Sachs Disease | 1 | 2022 | 52 | 0.170 |
Why?
|
| Male | 10 | 2016 | 31047 | 0.170 |
Why?
|
| Supine Position | 1 | 2001 | 34 | 0.170 |
Why?
|
| Prone Position | 1 | 2001 | 28 | 0.170 |
Why?
|
| Fluoroscopy | 1 | 2001 | 67 | 0.170 |
Why?
|
| Pain | 1 | 2023 | 399 | 0.170 |
Why?
|
| Blood Specimen Collection | 2 | 2012 | 20 | 0.160 |
Why?
|
| Fluorocarbons | 1 | 2001 | 52 | 0.160 |
Why?
|
| Drug Monitoring | 1 | 2001 | 202 | 0.150 |
Why?
|
| Female | 9 | 2016 | 34018 | 0.140 |
Why?
|
| Thalassemia | 1 | 2018 | 4 | 0.140 |
Why?
|
| Anemia, Hemolytic | 1 | 2018 | 13 | 0.140 |
Why?
|
| Shock, Hemorrhagic | 1 | 2018 | 18 | 0.140 |
Why?
|
| Shock | 1 | 2018 | 33 | 0.140 |
Why?
|
| Renal Replacement Therapy | 1 | 2018 | 23 | 0.140 |
Why?
|
| Anemia, Sickle Cell | 1 | 2018 | 65 | 0.140 |
Why?
|
| Length of Stay | 2 | 2014 | 828 | 0.130 |
Why?
|
| Epidermolysis Bullosa Dystrophica | 1 | 2017 | 14 | 0.130 |
Why?
|
| Graft vs Host Disease | 1 | 2018 | 113 | 0.130 |
Why?
|
| Heart Defects, Congenital | 1 | 2018 | 101 | 0.130 |
Why?
|
| Health Personnel | 1 | 2021 | 384 | 0.130 |
Why?
|
| Blood Transfusion | 1 | 2018 | 165 | 0.130 |
Why?
|
| Patient Care | 1 | 2017 | 79 | 0.130 |
Why?
|
| Prospective Studies | 4 | 2016 | 3308 | 0.120 |
Why?
|
| Splenic Neoplasms | 1 | 2016 | 7 | 0.120 |
Why?
|
| Quality of Life | 1 | 2023 | 1260 | 0.120 |
Why?
|
| Time Factors | 3 | 2016 | 3762 | 0.120 |
Why?
|
| Heart-Assist Devices | 1 | 2018 | 158 | 0.120 |
Why?
|
| Retrospective Studies | 3 | 2014 | 6872 | 0.120 |
Why?
|
| Propensity Score | 1 | 2016 | 190 | 0.110 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2016 | 128 | 0.110 |
Why?
|
| Erythrocyte Count | 3 | 2018 | 15 | 0.110 |
Why?
|
| Sepsis | 1 | 2018 | 296 | 0.110 |
Why?
|
| Kidney Neoplasms | 1 | 2016 | 173 | 0.110 |
Why?
|
| Accidents | 1 | 2014 | 11 | 0.110 |
Why?
|
| Risk Assessment | 2 | 2012 | 2102 | 0.100 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 740 | 0.100 |
Why?
|
| Odds Ratio | 1 | 2016 | 754 | 0.100 |
Why?
|
| Wounds and Injuries | 1 | 2016 | 250 | 0.100 |
Why?
|
| Liver Neoplasms | 1 | 2016 | 308 | 0.100 |
Why?
|
| Disease Models, Animal | 1 | 2001 | 2293 | 0.100 |
Why?
|
| Suicide, Attempted | 1 | 2014 | 111 | 0.100 |
Why?
|
| Intensive Care Units | 1 | 2016 | 420 | 0.100 |
Why?
|
| Risk Factors | 3 | 2012 | 5429 | 0.100 |
Why?
|
| Pancreatic Neoplasms | 1 | 2016 | 354 | 0.090 |
Why?
|
| Terminally Ill | 1 | 2012 | 17 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 464 | 0.090 |
Why?
|
| Drug Overdose | 1 | 2014 | 122 | 0.090 |
Why?
|
| Academic Medical Centers | 1 | 2014 | 306 | 0.090 |
Why?
|
| Platelet Transfusion | 2 | 2022 | 12 | 0.090 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 805 | 0.090 |
Why?
|
| Hospitals, Pediatric | 1 | 2012 | 55 | 0.090 |
Why?
|
| Cause of Death | 1 | 2012 | 221 | 0.090 |
Why?
|
| Canada | 2 | 2010 | 154 | 0.090 |
Why?
|
| Respiratory Function Tests | 1 | 2012 | 195 | 0.090 |
Why?
|
| Sex Distribution | 1 | 2012 | 252 | 0.090 |
Why?
|
| Drug Storage | 1 | 2011 | 23 | 0.080 |
Why?
|
| Linear Models | 1 | 2012 | 405 | 0.080 |
Why?
|
| Severity of Illness Index | 2 | 2018 | 1559 | 0.080 |
Why?
|
| Medical Audit | 1 | 2011 | 67 | 0.080 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2012 | 464 | 0.080 |
Why?
|
| Electronic Health Records | 1 | 2014 | 393 | 0.080 |
Why?
|
| Blood Gas Analysis | 2 | 2018 | 34 | 0.080 |
Why?
|
| Administration, Oral | 1 | 2011 | 371 | 0.080 |
Why?
|
| Lung Neoplasms | 1 | 2016 | 702 | 0.070 |
Why?
|
| Erythrocytes | 1 | 2010 | 146 | 0.070 |
Why?
|
| Patient Safety | 1 | 2012 | 259 | 0.070 |
Why?
|
| Treatment Outcome | 2 | 2012 | 5792 | 0.070 |
Why?
|
| Neoplasms | 1 | 2018 | 1368 | 0.070 |
Why?
|
| Incidence | 1 | 2012 | 1419 | 0.070 |
Why?
|
| Clinical Decision-Making | 2 | 2018 | 168 | 0.060 |
Why?
|
| Ventilator Weaning | 1 | 2007 | 21 | 0.060 |
Why?
|
| Cohort Studies | 1 | 2012 | 2620 | 0.060 |
Why?
|
| Surveys and Questionnaires | 1 | 2012 | 2757 | 0.050 |
Why?
|
| Blood Component Transfusion | 1 | 2022 | 11 | 0.040 |
Why?
|
| Plasma | 1 | 2022 | 38 | 0.040 |
Why?
|
| Young Adult | 1 | 2012 | 4809 | 0.040 |
Why?
|
| Anticonvulsants | 1 | 2022 | 104 | 0.040 |
Why?
|
| Therapeutic Irrigation | 1 | 2001 | 17 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2007 | 2483 | 0.040 |
Why?
|
| Pulmonary Gas Exchange | 1 | 2001 | 43 | 0.040 |
Why?
|
| Sodium Chloride | 1 | 2001 | 65 | 0.040 |
Why?
|
| Respiratory Mechanics | 1 | 2001 | 56 | 0.040 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2001 | 95 | 0.040 |
Why?
|
| Random Allocation | 1 | 2001 | 200 | 0.040 |
Why?
|
| Tissue Distribution | 1 | 2001 | 293 | 0.040 |
Why?
|
| Ventilators, Mechanical | 1 | 2000 | 28 | 0.040 |
Why?
|
| Lung Injury | 1 | 2000 | 36 | 0.040 |
Why?
|
| Swine | 1 | 2001 | 394 | 0.040 |
Why?
|
| Hemodynamics | 1 | 2001 | 251 | 0.040 |
Why?
|
| IgA Deficiency | 1 | 2018 | 3 | 0.040 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2018 | 7 | 0.040 |
Why?
|
| Vital Signs | 1 | 2018 | 11 | 0.040 |
Why?
|
| Decision Trees | 1 | 2018 | 48 | 0.040 |
Why?
|
| Acute Disease | 1 | 2000 | 663 | 0.030 |
Why?
|
| United States | 2 | 2010 | 8093 | 0.030 |
Why?
|
| Stem Cell Transplantation | 1 | 2018 | 79 | 0.030 |
Why?
|
| Survival Rate | 1 | 2000 | 844 | 0.030 |
Why?
|
| Consensus | 1 | 2018 | 176 | 0.030 |
Why?
|
| Animals | 3 | 2016 | 21345 | 0.030 |
Why?
|
| Deoxycytidine | 1 | 2016 | 45 | 0.030 |
Why?
|
| Albumins | 1 | 2016 | 43 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2016 | 286 | 0.030 |
Why?
|
| Paclitaxel | 1 | 2016 | 102 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2016 | 203 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2016 | 222 | 0.030 |
Why?
|
| Neovascularization, Pathologic | 1 | 2016 | 140 | 0.030 |
Why?
|
| Dependovirus | 1 | 2022 | 751 | 0.030 |
Why?
|
| Polyethylene Glycols | 1 | 2016 | 173 | 0.030 |
Why?
|
| Inpatients | 1 | 2017 | 319 | 0.030 |
Why?
|
| Genetic Therapy | 1 | 2022 | 839 | 0.030 |
Why?
|
| Skin | 1 | 2017 | 422 | 0.030 |
Why?
|
| Age Factors | 1 | 2016 | 1586 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2016 | 1038 | 0.020 |
Why?
|
| Materials Management, Hospital | 1 | 2010 | 1 | 0.020 |
Why?
|
| Adult | 1 | 2000 | 17358 | 0.010 |
Why?
|
| Mice | 1 | 2016 | 11119 | 0.010 |
Why?
|